More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$6.25B
EPS
-5.11
P/E ratio
--
Price to sales
13.24
Dividend yield
--
Beta
1.3513
Previous close
$47.78
Today's open
$47.12
Day's range
$44.07 - $47.41
52 week range
$37.06 - $95.49
show more
CEO
Christopher Anzalone
Employees
711
Headquarters
Pasadena, CA
Exchange
Nasdaq Global Select
Shares outstanding
141368004
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Arrowhead Pharmaceuticals Q4 Earnings Call Highlights
Arrowhead Pharmaceuticals NASDAQ: ARWR is preparing for a potential U.S. launch of its drug REDEMPLO in a larger patient population in the second quarter of 2027, as the company works to turn growing prescription demand for the medicine into paid treatments.
MarketBeat • Nov 13, 2026

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript
Seeking Alpha • Nov 13, 2026

Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting a conference call today, November 12, 2026, at 4:30 p.m. ET to discuss the results. “Arrowhead has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, there is now a company that is beginning to translate promise into real patient outc.
Business Wire • Nov 12, 2026

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026 Jefferies Global Healthcare Conference in London – November 16-19, 2026Type: Fireside Chat PresentationDate/Time: November 18, 2026, 11:00 am GMTCiti's 2026 Global Healthcare Conference – November 30 - December 3, 2026Type: Fireside Chat PresentationDate/Time: December 2, 2026, 2:20 pm ESTPiper Sandler 38th Annual Hea.
Business Wire • Nov 9, 2026

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. The presentations included multiple studies of plozasiran in patients with familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG), and interim results from a Phase 1/2a study of investigational ARO-DIMER-PA.
Business Wire • Nov 7, 2026

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases financial and operational flexibility. The transaction retires Arrowhead's existing $400 million Sixth Street facility at a $68 million discount to the contractual minimum repayment amount and establishes a new $400 million Si.
Business Wire • Nov 4, 2026

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its financial results for the 2026 fiscal year ended September 30, 2026.Webcast and Conference Call DetailsInvestors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours.
Business Wire • Nov 3, 2026

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week's American Heart Association Scientific Sessions in Chicago. AHA 2026 Oral Presentations Date & Time: Saturday, November 7, 3:15 – 4:30 pm CT Session Title: FS.05: Featured Science Session on Novel Lipid Lowering Therapies Location: Learning Studio 2‚ Science and Technology Hall‚ South Hall Title: First-in-Human Trial of a Dual Functional RNAi Mo.
Business Wire • Nov 2, 2026

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) will have access to a newly licensed new treatment option available on the NHS to reduce extremely high levels of triglycerides (a type of fat) in their bloodstreams, if the response to diet and conventional triglyceride lowering therapies has been inadequate. REDEMPLO® (plozasi.
Business Wire • Oct 27, 2026

Top 3 Health Care Stocks That Could Blast Off In October
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Benzinga • Oct 21, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Arrowhead Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.